Merck: Why Investors Should Remain Bullish Despite Patent Risks
Source: SeekingAlpha
2026-02-22 08:00:00 ET
In my last article, "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge" , I have been talking mainly about Merck's (MRK) Q3 results and the efficacy of Keytruda+Pfizer’s (PFE) Padcev in the KEYNOTE-905....
Read the full article on Seeking Alpha
For further details see:
Merck: Why Investors Should Remain Bullish Despite Patent Risks
Sanofi
NASDAQ: SNY
SNY Trading
-0.04% G/L:
$44.915 Last:
484,196 Volume:
$44.86 Open:
SNY Latest News
March 18, 2026 12:52:09 pm
Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale
February 23, 2026 01:42:29 pm
Kraig Biocraft Laboratories Featured on the Cover of National Geographic
February 18, 2026 08:45:56 am
It's Not Synthetic, It's Real. Kraig Labs Nears Spider Silk Breakthrough
SNY Stock Data
$119,804,457,217
2,430,957,423
N/A
389
N/A
Pharmaceuticals
Healthcare
FR
Paris
